Dr. John E. Wagner, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
516 Delaware St Se, Pwb Fifth Floor, Suite 5-100, Clinic 5b
Minneapolis, MN 55455
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MN license 34354 -
Pediatrics Physician
MN license 34354
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $26,533 in research payments for these studies, mostly to the institutions running them.
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell Inc. · Completed · NCT02730299
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.